Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients with ESR1-mutated, ER-positive, HER2-negative ABC By Ogkologos - June 4, 2025 430 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Young Man’s “Water You Can Eat” Invention for His Grandma with... July 8, 2020 Adding Blinatumomab to Chemotherapy Improves DFS in Patients with Newly Diagnosed... January 13, 2025 FDA Approves Cosibelimab-ipdl for Metastatic or Locally Advanced Cutaneous Squamous Cell... January 31, 2025 Efficacy and Safety of Datopotamab Deruxtecan in Patients with Pretreated Advanced/Metastatic... January 27, 2025 Load more HOT NEWS Duration of Bevacizumab Maintenance of 15 Months Remains the Standard in... First-Line Serplulimab in Combination with Chemotherapy Improves Survival in Patients with... Latest episode of our podcast for researchers Cemiplimab Prolongs Overall Survival Among Patients with Recurrent Cervical Cancer After...
